06/04/2026
ASCO 2026 HIGHLIGHTS
π A Series for the Community β From Your Oncologist
οΏΌ
Every year, over 45,000 oncologists, researchers, and cancer care professionals from around the world gather for one event: the ASCO Annual Meeting β the largest and most influential oncology conference on the planet.
For five days, the brightest minds in cancer research present their latest findings. Some are incremental. Some are promising. And once in a rare while β something happens that stops the room.
This year, that moment belonged to pancreatic cancer.
Pancreatic cancer is one of the hardest cancers we face. For decades, once patients progressed on first-line chemotherapy, the options were limited and the outcomes were devastating β most patients survived only 6 to 7 months.
At this year's ASCO, a new drug called daraxonrasib changed that story.
In a landmark phase III trial of 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib β a first-in-class oral drug that targets the RAS protein, the very engine that drives over 90% of pancreatic cancers β doubled overall survival compared to standard chemotherapy:
π 13.2 months vs. 6.6 months
π 60% reduction in the risk of death
π Only 1.2% of patients had to stop treatment due to side effects (vs. 11.2% with chemo)
And it wasn't just about living longer. Patients on daraxonrasib had less pain and better quality of life β something that matters deeply to every patient and family we care for.
When the results were presented, the audience β thousands of oncologists, many of whom have sat with patients and families through the hardest conversations β rose for a standing ovation. Not just for the data, but for what it represents: that even in the cancers we've struggled with the most, science is finally catching up.
οΏΌ
π What This Means for Our Patients:
For years, we've told pancreatic cancer patients that second-line options were limited. This changes the conversation. Daraxonrasib is an oral medication - no infusion chair needed and it works across nearly all pancreatic cancers because it targets the RAS mutations found in over 90% of cases.
This is what progress looks like. And this is why we keep fighting.
οΏΌ
π Stay tuned β every few days, I'll share another highlight from ASCO 2026 that matters for our community.
Next up: a game-changer in triple-negative breast cancer.